Carcinoma Cancer Articles & Analysis
11 news found
xCures, Inc. is proud to announce their partnership with Travera, and the launch of a decentralized clinical trial that provides patients with advanced carcinoma a functional profile of their cancer cells. Advanced carcinoma patients often have malignant fluid drained to provide symptomatic relief. ...
ByxCures
Session date/time: May 16, 5:30 - 6:30 p.m. EDT Session title: Cancer - Targeted Gene and Cell Therapy I Abstract: #352 Poster: #M-233 Activation regulated gene circuit for controlling payload expression in cell therapies, Hung et al. ...
Our synthetic biology platform utilizes allogeneic chimeric antigen receptor natural killer (CAR-NK) cells, outfitted with these Gene Circuit technologies, to target particularly challenging liquid and solid oncology indications, including acute myeloid leukemia, hepatocellular carcinoma, and colorectal cancer. We have also demonstrated the breadth of our Gene ...
Senti Bio, a leading gene circuit company, today announced the acceptance of an abstract for presentation at the American Association for Cancer Research (AACR) annual meeting in New Orleans taking place April 8–13, 2022. ...
Our synthetic biology platform utilizes allogeneic chimeric antigen receptor natural killer (CAR-NK) cells, outfitted with these Gene Circuit technologies, to target particularly challenging liquid and solid oncology indications, including acute myeloid leukemia, hepatocellular carcinoma, and colorectal cancer. We have also demonstrated the breadth of our Gene ...
One complete response, and a disease control rate of 64% with stable disease for ≥16 weeks in two patients, as of the data cutoff Data presented today at the International Liver Cancer Association meeting at 12:25 p.m. CET Adaptimmune Therapeutics plc (Nasdaq: ADAP), a leader in cell therapy to treat cancer, announced updated data from its Phase 1 ...
Tom is working with Michelson to develop AI software that will process images of basal cell carcinoma, the most common form of skin cancer affecting millions worldwide, scanned by dermatologists using the innovative VivoSight™ OCT scanner already manufactured by Michelson Diagnostics. The AI will rapidly detect markers for basal cell ...
SFA is focused on proprietary drugs to treat chronic inflammation, which been implicated in a wide range of diseases, including Hepatocellular Carcinoma (liver cancer), Psoriatic Arthritis, Rheumatoid Arthritis, Lupus (SLE), Inflammatory Bowel Disease (IBD), Crohn’s Disease, and Chronic Liver Disease. SFA currently has six drugs under development, and is ...
Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending that the European label for KEYTRUDA, Merck’s anti-PD-1 therapy, be updated to include data from KEYNOTE-361, a Phase 3, open-label trial that evaluated KEYTRUDA ...
These NCEs will be targeting basal cell carcinoma, pancreatic cancer, and glioblastoma with the ultimate future goal of establishing new standards of care for cancer patients. ...
This agent has the potential to make polyps light up like light bulbs – allowing clinicians to detect and remove more polyps, prevent more cancers and save more lives.” Evidence that colorectal cancer can be prevented by the removal of pre-cancerous lesions and polyps (abnormal growth of tissue) is strong. The EMI-137 agent can help ...